MEDIHONEY Is Associated With Reduction In Wound Size
Derma Sciences's study involving MEDIHONEY Wound & Burn Dressing shows that use of the dressings are associated with a reduction in wound size, possibly driven in part by a significant reduction in overall wound pH. The 20-patient study will be published in the May edition of the International Wound Journal. The article -- "The impact of Manuka honey dressings on the surface pH of chronic wounds" -- was written by Georgina T. Gethin, Seamus Cowman and Ronan Conroy, all of the Royal College of Surgeons, Dublin, Ireland. The May edition of the International Wound Journal is a special edition of this globally-recognized peer-reviewed journal, and will be distributed to the attendees of the upcoming World Union of Wound Healing Societies conference, to be held in Toronto this June 4-8.
According to the abstract for the article, the authors evaluated the progression of 20 non-healing ulcers of various etiologies following application of the dressings over a period of two weeks. The dressings were provided by Derma Sciences' global commercialization partner, Comvita New Zealand, Inc. The authors cite their rationale for researching pH modulation in chronic wounds as follows:
"Chronic non-healing wounds have an elevated alkaline environment. The acidic pH of Manuka honey makes it a potential treatment for lowering wound pH, but the duration of the effect is unknown. Lowering wound pH can potentially reduce protease activity, increase fibroblast activity and increase oxygen release, consequently aiding wound healing."
After two weeks of treatment with the dressings, the authors concluded that, for this group of previously non-healing ulcers, "the use of Manuka honey dressings was associated with a statistically significant decrease in wound pH and a reduction in wound size." Significant wound progression during a two-week period is noted as a strong predictor of good wound healing outcomes.
Commenting on the article, Derma Sciences CEO Edward Quilty said, "Method of action is obviously an important component to having a better understanding of a medical device. Based on the results clinicians have seen all over the world, and recently here since our launch in the US and Canada, we have known for quite some time that the dressings work. Now we are getting a better understanding as to 'why'. Providing the answer to this question will no doubt increase product usage, as it makes clinicians feel more comfortable that the product has been studied thoroughly, it is effective, and we understand why it is effective. Although pH modulation and the product's high osmolarity have long been thought to contribute to the effectiveness of the product, it is rewarding to see these beliefs are being confirmed through good, well structured trials."
He also added, "This is yet another important study focused on non-healing or recalcitrant wounds that are not progressing with other advanced wound care modalities. It will only help to improve MEDIHONEY's growing reputation as an effective dressing to 'kick-start' the healing process. This is what clinicians are reporting to us after their lengthy clinical evaluations. As we planned, we believe clinicians are gaining significant confidence in our dressing for very troublesome wounds. Once this is established in the market, it then becomes only a matter of time before the dressing is more commonly used even from the onset of a wound. This will be reflected in growing product sales as we ramp up throughout 2008 and into 2009."